177Lu-AB-3PRGD2

· The First Affiliated Hospital of Xiamen University

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for 177Lu-AB-3PRGD2, covering 2024-06-13 to 2025-08-08. Get the full timeline:

Most recent: Clinical Trial Update: Clinical Evaluation of 177Lu-AB-3PRGD2 in Various Solid Tumors With Integrin αvβ3 Positive Expression [Phase 1]